# CRISPR-Cas immunity in bacteria: Discovery

Source page: https://www.materialinsights.org/science/crispr_mechanism/sci-discovery/

#### The story

How the idea was found and came to be accepted

Odd repeated stretches of DNA had been seen in microbes for years before anyone knew their purpose. Francisco Mojica, in Spain, described them in 1993 ^[1], and the name CRISPR first appeared in print in 2002 ^[1]. In 2005 Mojica reported that the pieces between the repeats matched the DNA of viruses that infect bacteria, and he suggested, correctly, that they form an adaptive immune system ^[1]. In 2007 Philippe Horvath, Rodolphe Barrangou and colleagues showed by experiment that bacteria take up viral DNA and so resist the next attack ^[1]. The next step was to find out how the cut is directed. In 2012 Emmanuelle Charpentier and Jennifer Doudna showed that the system could be redirected to cut a chosen DNA ^[2, 3], and they shared the 2020 Nobel Prize in Chemistry ^[2].

as of 2026-11-12

#### People

The people behind it, their years and what each contributed

| Name | Years | Contribution |
|---|---|---|
| Emmanuelle Charpentier | born 1968 | With Doudna, found in 2012 how the system's Cas9 enzyme cuts DNA ^[2] |
| Jennifer Doudna | born 1964 | With Charpentier, showed in 2012 that the system can be made to cut a chosen DNA ^[3] |

as of 2026-11-12. Francisco Mojica, who first proposed the immune role [1], is left out of the table because the sources opened give no life years for him.

#### Milestones

The key moments, year by year

| Year | Event |
|---|---|
| 1993 | Mojica describes the repeated stretches now called a CRISPR locus ^[1] |
| 2002 | The term CRISPR is first used in print ^[1] |
| 2005 | Mojica finds the spacers match viral DNA and proposes an immune role ^[1] |
| 2007 | Experiments show bacteria gain resistance by storing viral DNA ^[1] |
| 2012 | Charpentier and Doudna show the system can be redirected to a chosen DNA ^[1, 3] |
| 2020 | Charpentier and Doudna share the Nobel Prize in Chemistry ^[2] |
| 2023 | The UK licenses Casgevy, the first medicine made using CRISPR ^[5] |

as of 2026-11-12

#### Sources

1. [CRISPR Timeline](https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline) Broad Institute of MIT and Harvard (a party to the CRISPR patent dispute; its account of who did what first is its own)
2. [Emmanuelle Charpentier](https://www.britannica.com/biography/Emmanuelle-Charpentier) Encyclopaedia Britannica
3. [Jennifer Doudna](https://www.britannica.com/print/article/2033401) Encyclopaedia Britannica
4. [MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia](https://www.gov.uk/government/news/mhra-authorises-world-first-gene-therapy-that-aims-to-cure-sickle-cell-disease-and-transfusion-dependent-thalassemia) Medicines and Healthcare products Regulatory Agency (GOV.UK), 2023

## Other sections

- [Summary](https://www.materialinsights.org/science/crispr_mechanism/index.md)
- [The idea](https://www.materialinsights.org/science/crispr_mechanism/sci-idea/index.md)
- [Technologies](https://www.materialinsights.org/science/crispr_mechanism/sci-technologies/index.md)
